JP2017537905A - アルツハイマー病の治療法 - Google Patents

アルツハイマー病の治療法 Download PDF

Info

Publication number
JP2017537905A
JP2017537905A JP2017527872A JP2017527872A JP2017537905A JP 2017537905 A JP2017537905 A JP 2017537905A JP 2017527872 A JP2017527872 A JP 2017527872A JP 2017527872 A JP2017527872 A JP 2017527872A JP 2017537905 A JP2017537905 A JP 2017537905A
Authority
JP
Japan
Prior art keywords
patient
dose
body weight
antibody
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017527872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537905A5 (enExample
Inventor
ジェイムズ エル． フェレーロ，
ジェイムズ エル． フェレーロ，
レスリー ルジーン ウイリアムズ，
レスリー ルジーン ウイリアムズ，
ジェフリー ジョセフ セヴィニー，
ジェフリー ジョセフ セヴィニー，
Original Assignee
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー, バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー filed Critical バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー
Publication of JP2017537905A publication Critical patent/JP2017537905A/ja
Publication of JP2017537905A5 publication Critical patent/JP2017537905A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017527872A 2014-12-02 2015-12-02 アルツハイマー病の治療法 Withdrawn JP2017537905A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462086674P 2014-12-02 2014-12-02
US62/086,674 2014-12-02
US201562111874P 2015-02-04 2015-02-04
US62/111,874 2015-02-04
US201562149133P 2015-04-17 2015-04-17
US62/149,133 2015-04-17
US201562195119P 2015-07-21 2015-07-21
US62/195,119 2015-07-21
PCT/IB2015/002465 WO2016087944A2 (en) 2014-12-02 2015-12-02 Method for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020004429A Division JP2020055880A (ja) 2014-12-02 2020-01-15 アルツハイマー病の治療法

Publications (2)

Publication Number Publication Date
JP2017537905A true JP2017537905A (ja) 2017-12-21
JP2017537905A5 JP2017537905A5 (enExample) 2018-12-20

Family

ID=55358010

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017527872A Withdrawn JP2017537905A (ja) 2014-12-02 2015-12-02 アルツハイマー病の治療法
JP2020004429A Withdrawn JP2020055880A (ja) 2014-12-02 2020-01-15 アルツハイマー病の治療法
JP2021127999A Withdrawn JP2021169536A (ja) 2014-12-02 2021-08-04 アルツハイマー病の治療法
JP2022188107A Withdrawn JP2023011002A (ja) 2014-12-02 2022-11-25 アルツハイマー病の治療法
JP2025167679A Pending JP2025182058A (ja) 2014-12-02 2025-10-03 アルツハイマー病の治療法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020004429A Withdrawn JP2020055880A (ja) 2014-12-02 2020-01-15 アルツハイマー病の治療法
JP2021127999A Withdrawn JP2021169536A (ja) 2014-12-02 2021-08-04 アルツハイマー病の治療法
JP2022188107A Withdrawn JP2023011002A (ja) 2014-12-02 2022-11-25 アルツハイマー病の治療法
JP2025167679A Pending JP2025182058A (ja) 2014-12-02 2025-10-03 アルツハイマー病の治療法

Country Status (12)

Country Link
US (1) US10842871B2 (enExample)
EP (1) EP3227329A2 (enExample)
JP (5) JP2017537905A (enExample)
KR (3) KR20170088360A (enExample)
AU (3) AU2015356773B2 (enExample)
CA (1) CA2967897A1 (enExample)
EA (1) EA201791199A1 (enExample)
IL (3) IL285722B2 (enExample)
MA (1) MA41115A (enExample)
MX (2) MX385045B (enExample)
WO (1) WO2016087944A2 (enExample)
ZA (1) ZA202107358B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025517623A (ja) * 2022-05-03 2025-06-10 エフ． ホフマン－ラ ロシュ アーゲー アミロイド関連画像異常のインシリコ予測

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP2019517540A (ja) * 2016-06-07 2019-06-24 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー アルツハイマー病を治療する方法
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109952097A (zh) * 2016-07-29 2019-06-28 生物切萨皮克有限责任公司 治疗或预防与阿尔茨海默病治疗相关的淀粉样蛋白相关成像异常的方法
IL266114B2 (en) * 2016-10-27 2025-03-01 Eisai R&D Man Co Ltd A preparation containing anti-Abeta protiferyl antibody and BETA-SECRETASE inhibitor BACE1 for the treatment of Alzheimer's disease
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
LT3672631T (lt) 2017-08-22 2023-04-25 Biogen Ma Inc. Farmacinės kompozicijos, kurių sudėtyje yra antikūnų prieš beta amiloidą
JP7541505B2 (ja) * 2018-07-24 2024-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病の治療及び予防方法
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
US20240270830A1 (en) * 2021-06-07 2024-08-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250319105A1 (en) 2021-06-11 2025-10-16 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
KR102753583B1 (ko) 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
WO2023183623A1 (en) 2022-03-25 2023-09-28 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
JPWO2023210405A1 (enExample) 2022-04-25 2023-11-02
WO2024229290A1 (en) 2023-05-02 2024-11-07 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
ES2155099T3 (es) 1993-10-27 2001-05-01 Elan Pharm Inc Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
DE69839808D1 (de) 1997-04-09 2008-09-11 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2349434A1 (en) 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
WO2001031056A2 (fr) 1999-10-27 2001-05-03 Universite De Liege Methode de detection par pcr
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030028904A1 (en) 2001-04-19 2003-02-06 Gumienny Tina L. Genes involved in engulfment of dying cells and cell migration
AU2002329775C1 (en) 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
US7414111B2 (en) 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SG173214A1 (en) 2002-04-19 2011-08-29 Univ Toronto Immunological methods and compositions for the treatment of alzhemier's disease
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
JP4690046B2 (ja) 2002-11-22 2011-06-01 中外製薬株式会社 病巣組織に対する抗体
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20060240485A1 (en) 2003-04-24 2006-10-26 Universitat Zurich Method of monitoring immunotherapy
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
DK1720909T3 (da) 2004-02-23 2012-01-30 Lilly Co Eli Anti-Abeta antistof
ATE512365T1 (de) 2004-04-15 2011-06-15 Univ Florida Map-2 proteolytische produkte als diagnostische biomarker fur neuralen verletzungen
US7763249B2 (en) 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
US20110142858A1 (en) 2004-06-07 2011-06-16 Ramot At Tel Aviv University Ltd. Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2006066171A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
CA2599792A1 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006116192A2 (en) 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
CA2629463A1 (en) 2005-11-14 2008-02-21 Scott A. Small Imaging correlates of neurogenesis with mri
EP1951892A4 (en) 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
CA2637472A1 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
WO2007067959A2 (en) * 2005-12-07 2007-06-14 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
KR101591206B1 (ko) 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ES2641897T3 (es) 2007-01-05 2017-11-14 University Of Zurich Procedimiento para proporcionar moléculas de unión y diana específicas de una enfermedad
MX2009007406A (es) 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
HUE035762T2 (en) 2007-03-13 2018-05-28 Univ Zuerich Monoclonal Human Tumor-Specific Antibody
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011127A (es) 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
JP2008309778A (ja) 2007-05-11 2008-12-25 Daiichi Sankyo Co Ltd ポリペプチドの検出又は定量方法、及び装置
JP2010532976A (ja) 2007-06-08 2010-10-21 ユニヴェルシテ・ドゥ・ラ・メディテラネ 膵臓腫瘍を治療するための組成物および方法
US8022268B2 (en) 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
EP2185592B1 (en) 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
RU2504551C2 (ru) 2007-09-26 2014-01-20 УЗ ФАРМА ГмбХ Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
WO2009043103A1 (en) 2007-10-02 2009-04-09 Csl Limited Therapeutic antibody purification method and method of use
CA2702880A1 (en) 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to a beta oligomer, and use thereof
US7771957B2 (en) 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
ME01026B (me) 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
PL2246427T3 (pl) 2008-02-08 2017-06-30 Immunas Pharma, Inc. Przeciwciała zdolne do wiązania się swoiście do oligomerów amyloidu beta i ich stosowanie
TR201901497T4 (tr) 2008-04-29 2019-02-21 Bioarctic Ab Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
CN102388067A (zh) 2008-09-19 2012-03-21 米迪缪尼有限公司 定向于cd105的抗体及其用途
HUE027027T2 (en) 2008-11-13 2016-08-29 Modgene Llc Reduction of amyloid beta load in non-brain tissue
EP2949666B1 (en) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20110237537A1 (en) 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
DK2462161T3 (en) 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
JP5599454B2 (ja) 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US20110166035A1 (en) 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US20110152341A1 (en) 2009-12-22 2011-06-23 Probiodrug Ag Cleavage of b-amyloid precursor protein
GB201901818D0 (en) 2010-07-07 2019-04-03 Thermo Fisher Scient Gmbh Analyte mass spectrometry quantitation using a universal reporter
ME03661B (me) 2010-08-12 2020-07-20 Lilly Co Eli Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
AU2011315181B2 (en) 2010-10-11 2016-07-28 Biogen International Neuroscience Gmbh Human anti-tau antibodies
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
WO2012174262A2 (en) 2011-06-14 2012-12-20 Cenestra Llc Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP3964524A1 (en) 2011-10-28 2022-03-09 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
US20130164367A1 (en) 2011-12-08 2013-06-27 The Board Of Regents Of The University Of Texas System Treatment of neurodegenerative disease with creb-binding protein
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
AU2013314301B2 (en) 2012-09-12 2018-02-15 Neurimmune Holding Ag Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof
US20140272950A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict ssri response
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
WO2015006475A1 (en) 2013-07-12 2015-01-15 Biogen Idec International Neuroscience Gmbh Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
RS60774B1 (sr) 2013-12-20 2020-10-30 Neurimmune Holding Ag Lečenje transtiretinske (ttr) amiloidoze na bazi antitela i odgovarajuća antitela humanog porekla
JP6685912B2 (ja) 2014-02-08 2020-04-22 ジェネンテック， インコーポレイテッド アルツハイマー病治療方法
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
CA2954738A1 (en) 2014-07-29 2016-02-04 Neurimmune Holding Ag Human-derived anti-huntingtin (htt) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3430397B1 (en) 2016-03-14 2022-02-23 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
WO2014182631A1 (en) * 2013-05-06 2014-11-13 Baxter International Inc. Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALZHEIMER'S AND DEMENTIA, vol. Vol.10, SUPPL.4, JPN6019040061, July 2014 (2014-07-01), pages 25 - 041, ISSN: 0004281727 *
ALZHEIMER'S AND DEMENTIA, vol. Vol.9, No.4 SUPPL, JPN6019040060, July 2013 (2013-07-01), pages 290 - 1, ISSN: 0004281728 *
ALZHEIMER'S AND DEMENTIA, vol. Vol.9, No.4 SUPPL., JPN6019040059, July 2013 (2013-07-01), pages 689 - 4, ISSN: 0004281726 *
ALZHEIMERS DEMENT., vol. 7(4), JPN6020019661, 2011, pages 367 - 385, ISSN: 0004281729 *
LANCET NEUROL, vol. 11, JPN6020019663, 2012, pages 241 - 249, ISSN: 0004281730 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025517623A (ja) * 2022-05-03 2025-06-10 エフ． ホフマン－ラ ロシュ アーゲー アミロイド関連画像異常のインシリコ予測

Also Published As

Publication number Publication date
IL311405A (en) 2024-05-01
KR20170088360A (ko) 2017-08-01
WO2016087944A2 (en) 2016-06-09
KR20240152957A (ko) 2024-10-22
WO2016087944A3 (en) 2016-08-04
JP2025182058A (ja) 2025-12-11
IL285722A (en) 2021-09-30
AU2025201237A1 (en) 2025-03-20
CA2967897A1 (en) 2016-06-09
US20180333487A1 (en) 2018-11-22
MA41115A (fr) 2017-10-10
MX385045B (es) 2025-03-14
AU2015356773B2 (en) 2021-09-09
NZ770434A (en) 2024-10-25
US10842871B2 (en) 2020-11-24
JP2020055880A (ja) 2020-04-09
ZA202107358B (en) 2025-01-29
AU2021282448A1 (en) 2022-01-06
NZ731520A (en) 2021-08-27
IL285722B1 (en) 2024-04-01
IL252433A0 (en) 2017-07-31
JP2021169536A (ja) 2021-10-28
IL285722B2 (en) 2024-08-01
IL252433B (en) 2021-09-30
MX2021009053A (es) 2021-09-21
EP3227329A2 (en) 2017-10-11
AU2015356773A1 (en) 2017-05-25
MX2017006789A (es) 2018-01-11
JP2023011002A (ja) 2023-01-20
EA201791199A1 (ru) 2017-09-29
KR20220044874A (ko) 2022-04-11

Similar Documents

Publication Publication Date Title
JP2023011002A (ja) アルツハイマー病の治療法
US20220281963A1 (en) Methods for treating alzheimer's disease
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
CN120826223A (zh) 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病
US20240270830A1 (en) Methods for treating alzheimer's disease
NZ788486A (en) Methods for treating Alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200610

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210331